-- ACTengine(R) IMA200 clinical trial series continues scaling globally; 
      initial analysis for patients in ACTengine(R) dose escalation is on track 
      for Q1 2021 
 
 
   -- Expansion of UTHealth partnership secures cell therapy manufacturing 
      capacities until end of 2024 
 
 
   -- Positive pre-clinical data updates on ACTengine(R) IMA204 and first TCR 
      Bispecifics (TCER(TM)) program IMA401 
 
 
   -- Strengthened leadership team with appointment of Arnd Christ as Chief 
      Financial Officer and addition of Eliot Forster to Immatics' Board of 
      Directors 
 
 
   -- Cash and cash equivalents as well as other financial assets of EUR259.3 
      million ($303.6 million1) as of September 30, 2020 provide cash reach 
      into 2023 
 
 
 
 
 
   Tuebingen, Germany and Houston, TX, December 2, 2020 -- Immatics N.V. 
(NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company 
active in the discovery and development of T cell redirecting cancer 
immunotherapies, today reported financial results and provided a 
business update for the quarter ended September 30, 2020. 
 
   "The third quarter was highlighted by meaningful progress in our 
ACTengine(R) IMA200 clinical trial series. Seven clinical sites in 
Germany and the US are now initiated and screening patients. These 
advancements mark critical steps towards delivering our clinical 
milestones for the coming year including reporting on initial data for 
ACTengine(R) patients in dose escalation in Q1," said Harpreet Singh, 
Ph.D., CEO of Immatics. "In conjunction with our clinical and 
operational progress, we are pleased to further strengthen the Company's 
capabilities with the appointments of both Eliot Forster to the Board 
and Arnd Christ as Chief Financial Officer." 
 
   Third Quarter 2020 and Subsequent Company Progress 
 
   Adoptive Cell Therapy Programs 
https://www.globenewswire.com/Tracker?data=TfIVpRPmeYco_6LTAnGQnmPu5jZ7kvA4NU1_3Rhrw1sqm2a77qsaDW-AFjeFQ8b5TsNrF4VcaRHlkfjOJ3Kov8IYBLYSuR10-7aBOoMVtB5T3Ufqn6fMp6E7Qe5hMKtZbPOY6TQJn1XM6-fSzey3pw== 
 
 
 
   -- ACTengine(R) IMA200 Series -- Immatics continued to select and initiate 
      additional clinical trial sites in Germany and the US. The increased 
      patient enrollment seen at sites in Germany was able to mitigate the 
      impact of the global COVID-19 pandemic at US sites. These patients are 
      expected to be treated within the fourth quarter this year, moving 
      Immatics towards delivering the clinical milestones for ACTengine(R) in 
      the coming year. Combined initial data readout for ACTengine(R) programs, 
      IMA201, IMA202 and IMA203, continues to be expected in Q1 2021. Reported 
      initial data will focus on safety and pharmacodynamic data including 
      engraftment level, persistence and molecular phenotype of infused T cells 
      as well as clinical change of target tumor lesions. 
 
 
   -- ACTengine(R) IMA204 -- Immatics presented preclinical data from the 
      ACTengine(R) cell therapy program targeting the tumor microenvironment on 
      September 10. IMA204 is directed at a novel target, COL6A3 exon 6, which 
      is highly expressed in the tumor stroma of a variety of solid cancers. An 
      affinity-enhanced TCR candidate directed to this target demonstrated full 
      functionality in CD8+ and CD4+ T cells indicating that this TCR could be 
      employed in a next-generation ACTengine(R) approach without the need of 
      CD8 co-receptor transduction. Submission of an Investigational New Drug 
      (IND) application to the US Food and Drug Administration (FDA) for IMA204 
      remains anticipated for 2021. 
 
 
   -- ACTolog(R) IMA101 -- On November 10, Immatics presented topline data from 
      its clinical pilot trial IMA101, a personalized multi-target ACT approach 
      using the patient's own, non-engineered T cells. The trial demonstrated 
      feasibility and tolerability of this approach as well as very high 
      persistence of endogenous T cells directed against defined pHLA targets. 
      Clinical course observations in patients treated with T cells directed at 
      the tumor stroma target COL6A3 exon 6 warrant further exploration of this 
      target within ACTengine(R). The results also support further development 
      of a multi-target approach using multiple engineered TCRs simultaneously 
      in ACTengine(R). 
 
 
 
   https://www.globenewswire.com/Tracker?data=gQGKteno8Ql83QXG-2mPGlx3-D8g_YJ6IXtJpV-E8JU4_o4h3hVKFqfyZPA4pKuA9XM_H5GUbZi3v9FwwayGdkkd2cYiPRRWYo2nJoaum55n3SO-mNu_2co2YATG172- 
TCR Bispecifics Programs 
 
 
   -- IMA401 -- A preclinical data update from Immatics' first TCR Bispecifics 
      (TCER(TM)) program on October 29, delivered pre-clinical proof-of-concept 
      for IMA401 demonstrating complete remission of transplanted human tumors 
      in mice as well as favorable CMC characteristics. The IMA401 cancer 
      target, an HLA-A*02-bound peptide derived from both MAGEA4 and MAGEA8, 
      showed more than 5-fold higher target copy numbers per tumor cell than a 
      commonly used target peptide derived from MAGEA4. Submission of the 
      IMA401 IND/IMPD application remains expected by the end of 2021. 
 
 
   Corporate Development 
 
   Management and Board of Directors Updates 
 
 
   -- Eliot Forster, Ph.D., joined Immatics' Board of Directors as a new member 
      in September 2020. He brings to Immatics extensive experience, including 
      leadership of trailblazing biopharmaceutical companies in the field of 
      immuno-oncology as well as other therapeutic areas. 
 
 
   -- In October 2020, Arnd Christ joined Immatics' leadership team as Chief 
      Financial Officer (CFO). He was previously the CFO of Nasdaq-listed 
      InflaRx and brings nearly two decades of experience serving as the CFO of 
      both private and public biotechnology companies. 
 
 
 
   Collaborations and Strategic Alliances 
 
 
   -- On August 6, Immatics announced the extension of its strategic alliance 
      with UTHealth. The continued collaboration will provide Immatics 
      exclusive access to three cGMP suites enabling manufacturing and supply 
      of its ACT products for current and upcoming Phase 1 clinical trials in 
      the US and Europe for an additional four years until end of 2024. 
 
 
 
 
   Third Quarter 2020 Financial Results 
 
   Cash Position: Cash and cash equivalents as well as other financial 
assets sum up to EUR259.3 million ($303.6 million(1) ) as of September 
30, 2020 compared to EUR86.1 million ($100.8 million(1) ) as of June 30. 
The increase is mainly due to the business combination with ARYA 
Sciences Acquisition Corporation completed in July 2020 (ARYA merger) 
and the concurrent PIPE Financing. 
 
   Revenue: Total revenue, consisting of revenue from collaboration 
agreements, was EUR7.8 million ($9.1 million(1) ) for the three months 
ended September 30, 2020, compared to EUR5.1 million ($6.0 million(1) ) 
for the three months ended September 30, 2019. 
 
   Research and Development Expenses: R&D expenses were EUR17.5 million 
($20.5 million(1) ) for the three months ended September 30, 2020, 
compared to EUR10.2 million ($11.9 million(1) ) for the three months 
ended September 30, 2019. The increase is mainly due to increased 
share-based compensation (EUR4.6 million; $5.4 million(1) ). 
 
   General and Administrative Expenses: G&A expenses were EUR9.2 million 
($10.8 million(1) ) for the three months ended September 30, 2020, 
compared to EUR2.7 million ($3.2 million(1) ) for the three months ended 
September 30, 2019. The increase is mainly due to increased share-based 
compensation (EUR3.6 million; $4.2 million(1) ) as well as one-time 
transaction costs of the NASDAQ listing in connection with the ARYA 
merger in July. 
 
   Net Loss: Net loss was EUR177.1 million ($207.3 million(1) ) for the 
three months ended September 30, 2020, compared to EUR5.0 million ($5.9 
million(1) ) for the three months ended September 30, 2019 of which 
EUR152.8 million ($178.9 million(1) ) resulted from a one-time, non-cash 
expense in connection with the ARYA merger. The main part of this 
EUR152.8 million ($178.9 million(1) ) non-cash expense resulted from the 
share price increase between signing and closing of the ARYA merger. For 
detailed information, please refer to Note 9 of the Notes to the 
Financial Statements. 
 
   Upcoming Investor Conferences 
 
 
   -- Piper Sandler Healthcare Conference -- December 1-3, 2020 
 
   -- 10th Annual SVB Leerink Global Healthcare Conference -- February 24-26, 
      2021 
 
 
 
 
   To see the full list of events and presentations, visit 
https://www.globenewswire.com/Tracker?data=Gi0CYCgDH8ysAfK8wGGFVpaWlVVMccg4GvMCSqNVucEOa-iPDRWBcYgftbeRFsY2k2pPHWhtH4psek_s0O_1_H2swrtR5Wu7g3v0TdtqRZjhlzULpswOcSGmVAydVPAnuWYmQhmGx-MyoHLMZutFW3TSJ7B8txj9SbmKfGn1nQY= 
www.investors.immatics.com/events-presentations. 
 
   Full financial statements can be found in the current report on Form 6-K 
filed with the Securities and Exchange Commission (SEC) and published on 
the SEC website under 
https://www.globenewswire.com/Tracker?data=zIRC1_QSJ1MxhYYq_0SvKuKJJRh8eM74XLTrngOO-B6EJSqZ4ENFKOeZbI-ym2e--JaOjRzZU4rF1PFnaIfEHEldrpdU_rNaQChft86GhFg= 
https://www.sec.gov/. 
 
   (1) All amounts translated using the exchange rate published by the 
European Central Bank in effect as of September 30, 2020 (1 EUR = 1.1708 
USD). 
 
   About Immatics 
 
   Immatics combines the discovery of true targets for cancer 
immunotherapies with the development of the right T cell receptors with 
the goal of enabling a robust and specific T cell response against these 
targets. This deep know-how is the foundation for our pipeline of 
Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships 
with global leaders in the pharmaceutical industry. We are committed to 
delivering the power of T cells and to unlocking new avenues for 
patients in their fight against cancer. 
 
   Immatics intends to use its website

(MORE TO FOLLOW) Dow Jones Newswires

December 02, 2020 07:00 ET (12:00 GMT)